<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>Biomarker</th>
      <th>Gene</th>
      <th>Alteration type</th>
      <th>Alteration</th>
      <th>Targeting</th>
      <th>Drug status</th>
      <th>Drug family</th>
      <th>Drug</th>
      <th>Association</th>
      <th>Evidence level</th>
      <th>Assay type</th>
      <th>Source</th>
      <th>Curator</th>
      <th>Curation date</th>
      <th>Primary Tumor type</th>
      <th>Metastatic Tumor Type</th>
      <th>TCGI included</th>
      <th>Comments</th>
      <th>Drug full name</th>
      <th>Primary Tumor type full name</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>EZH2 (A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G)</td>
      <td>EZH2</td>
      <td>MUT</td>
      <td>EZH2:A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EZH2 inhibitor</td>
      <td>Tazemetostat</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma;PMID:33035457</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>FL</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FDA granted accelerated approval to tazemetostat for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.</td>
      <td>Tazemetostat (EZH2 inhibitor)</td>
      <td>Follicular lymphoma</td>
    </tr>
    <tr>
      <th>1</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Neratinib;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Neratinib (ERBB2 inhibitor) + Capecitabine (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>2</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Pertuzumab;Trastuzumab;Docetaxel</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:23801166</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Pertuzumab (ERBB2 inhibitor)+ Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>3</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Pertuzumab;Trastuzumab;Docetaxel</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:23801166</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Pertuzumab (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>4</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Hormone therapy</td>
      <td>Lapatinib;Letrozole</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:19786658</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Lapatinib (ERBB2 inhibitor) + Letrozole (Hormone therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
  </tbody>
</table>